Höcherl K, Wolf K, Castrop H, Ittner K P, Bucher M, Kees F, Grobecker H F, Kurtz A
Institut für Pharmakologie der Universität Regensburg, Germany.
Pflugers Arch. 2001 Sep;442(6):821-7. doi: 10.1007/s004240100615.
Based on recent evidence that renin gene and cyclooxygenase-2 (COX-2) expression in the rat kidney cortex increase in parallel under a variety of conditions, this study aimed to characterize the causal linkage between COX-2 and renin expression. Therefore, we semi-quantitated renocortical renin and COX-2 gene expression when the renin-angiotensin system (RAS) was inhibited by the angiotensin II (Ang II) AT1 receptor antagonist candesartan (15 mg/kg per day) and when COX-2 activity was blocked by celecoxib (20 mg/kg twice a day) in three rat strains (Sprague-Dawley, WKY and SHR) at ages of 5, 9 and 15 weeks. We observed that candesartan increased renin mRNA in all rats at all ages, the amplitude of stimulation being inversely related to age. Candesartan increased COX-2 mRNA in all three strains at 5 weeks, and in SD and WKY rats also at 9 weeks. In 9-week-old SHR and in 15-week-old rats of all three strains candesartan did not influence COX-2 mRNA levels. For all rat strains, strain-specific strong linear correlations existed between renocortical COX-2 and renin mRNA levels, both with and without candesartan treatment. The additional feeding of candesartan-treated rats with celecoxib did not change renin mRNA or COX-2 mRNA levels, whilst the renal excretion of sodium and renal cortical prostaglandin E2 concentration decreased by 26% and 60%, respectively. In summary, these findings, obtained when the renin system was activated by AT1 receptor blockade, indicate that Ang II is not required to stimulate COX-2 expression and that COX-2 activity is not required to stimulate renin expression. However, the renocortical expression of renin and of COX-2 appear to be highly coordinated under basal conditions and during inhibition of RAS, suggesting the existence of a common denominator for renin and COX-2 expression that remains to be elucidated.
基于近期的证据表明,在多种条件下大鼠肾皮质中的肾素基因和环氧化酶-2(COX-2)表达会平行增加,本研究旨在确定COX-2与肾素表达之间的因果联系。因此,我们在三种大鼠品系(Sprague-Dawley、WKY和SHR)5周、9周和15周龄时,当肾素-血管紧张素系统(RAS)被血管紧张素II(Ang II)AT1受体拮抗剂坎地沙坦(每天15 mg/kg)抑制时,以及当COX-2活性被塞来昔布(每天20 mg/kg,分两次给药)阻断时,对肾皮质肾素和COX-2基因表达进行了半定量分析。我们观察到,坎地沙坦在所有年龄段的所有大鼠中均增加了肾素mRNA水平,刺激幅度与年龄呈负相关。坎地沙坦在5周龄时增加了所有三个品系的COX-2 mRNA水平,在9周龄时也增加了SD和WKY大鼠的COX-2 mRNA水平。在9周龄的SHR和所有三个品系的15周龄大鼠中,坎地沙坦不影响COX-2 mRNA水平。对于所有大鼠品系,无论是否进行坎地沙坦治疗,肾皮质COX-2和肾素mRNA水平之间均存在品系特异性的强线性相关性。用塞来昔布额外喂养接受坎地沙坦治疗的大鼠,肾素mRNA或COX-2 mRNA水平没有变化,而钠的肾排泄和肾皮质前列腺素E2浓度分别降低了26%和60%。总之,这些在通过AT1受体阻断激活肾素系统时获得的结果表明,刺激COX-2表达不需要Ang II,刺激肾素表达也不需要COX-2活性。然而,在基础条件下和RAS抑制期间,肾皮质肾素和COX-2的表达似乎高度协调,这表明肾素和COX-2表达存在一个共同的决定因素,有待阐明。